NASDAQ:CDXC - Chromadex Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.56 -0.23 (-4.80 %) (As of 05/19/2019 06:33 AM ET)Previous Close$4.56Today's Range$4.55 - $4.7852-Week Range$2.79 - $5.00Volume135,864 shsAverage Volume203,864 shsMarket Capitalization$253.17 millionP/E RatioN/ADividend YieldN/ABeta1.12 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California. Receive CDXC News and Ratings via Email Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CDXC Previous Symbol CUSIPN/A CIK1386570 Webwww.chromadex.com Phone310-388-6706Debt Debt-to-Equity Ratio0.07 Current Ratio2.24 Quick Ratio1.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$31.56 million Price / Sales8.02 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book12.00Profitability EPS (Most Recent Fiscal Year)($0.61) Net Income$-33,320,000.00 Net Margins-94.78% Return on Equity-108.84% Return on Assets-72.46%Miscellaneous Employees100 Outstanding Shares55,520,000Market Cap$253.17 million Next Earnings Date8/8/2019 (Estimated) OptionableOptionable Chromadex (NASDAQ:CDXC) Frequently Asked Questions What is Chromadex's stock symbol? Chromadex trades on the NASDAQ under the ticker symbol "CDXC." How were Chromadex's earnings last quarter? Chromadex Corp (NASDAQ:CDXC) issued its earnings results on Thursday, May, 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.04. The company earned $10.05 million during the quarter, compared to analyst estimates of $9.80 million. Chromadex had a negative return on equity of 108.84% and a negative net margin of 94.78%. View Chromadex's Earnings History. When is Chromadex's next earnings date? Chromadex is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Chromadex. What price target have analysts set for CDXC? 2 analysts have issued 1 year price targets for Chromadex's stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate Chromadex's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price. View Analyst Price Targets for Chromadex. What is the consensus analysts' recommendation for Chromadex? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chromadex in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chromadex. What are Wall Street analysts saying about Chromadex stock? Here are some recent quotes from research analysts about Chromadex stock: 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (5/8/2019) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We apply a 26.6x EV-to-EBITDA multiple applied to our 2020 EBITDA per share estimate of $0.35, discounted back at a 12% rate, which yields a price objective of approximately $7.00 per share." (4/25/2019) Has Chromadex been receiving favorable news coverage? Headlines about CDXC stock have been trending somewhat positive recently, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chromadex earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the next few days. Who are some of Chromadex's key competitors? Some companies that are related to Chromadex include Canopy Rivers (RIV), CV Sciences (CVSI), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), FitLife Brands (FTLF), GLG Life Tech (GLGLF), True Drinks (TRUU), Tauriga Sciences (TAUG), Nutra Pharma (NPHC), Entia Biosciences (ERGO) and Actelion (ALIOF). What other stocks do shareholders of Chromadex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chromadex investors own include TransEnterix (TRXC), Heron Therapeutics (HRTX), Tilray (TLRY), Athersys (ATHX), Glu Mobile (GLUU), Axsome Therapeutics (AXSM), CELYAD SA/ADR (CYAD), Mesoblast (MESO), Sorrento Therapeutics (SRNE) and Wheeler Real Estate Investment Trust (WHLR). Who are Chromadex's key executives? Chromadex's management team includes the folowing people: Mr. Frank Louis Jaksch Jr., Co-Founder & Exec. Chairman (Age 51)Mr. Robert N. Fried, CEO & Director (Age 59)Mr. Kevin M. Farr, Chief Financial Officer (Age 61)Mr. Ben Shichman, Chief Technology OfficerDr. Matthew Roberts, Chief Scientific Officer & Sr. VP of Innovation Who are Chromadex's major shareholders? Chromadex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.50%), Tieton Capital Management LLC (2.27%), Northern Trust Corp (0.75%), Granite Investment Partners LLC (0.30%), Charles Schwab Investment Management Inc. (0.15%) and Miracle Mile Advisors LLC (0.12%). Company insiders that own Chromadex stock include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer, Stephen A Block and Stephen R Allen. View Institutional Ownership Trends for Chromadex. Which institutional investors are selling Chromadex stock? CDXC stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Voya Investment Management LLC and MML Investors Services LLC. View Insider Buying and Selling for Chromadex. Which institutional investors are buying Chromadex stock? CDXC stock was purchased by a variety of institutional investors in the last quarter, including Tieton Capital Management LLC, Granite Investment Partners LLC, Miracle Mile Advisors LLC, The Manufacturers Life Insurance Company , BlackRock Inc., Spark Investment Management LLC, Charles Schwab Investment Management Inc. and Woodard & Co. Asset Management Group Inc. ADV. Company insiders that have bought Chromadex stock in the last two years include Frank L Jaksch Jr, Kevin M Farr, Mark J Friedman, River Ventures Ltd Champion, Robert N Fried, Step Holdings Ltd Pioneer and Stephen R Allen. View Insider Buying and Selling for Chromadex. How do I buy shares of Chromadex? Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Chromadex's stock price today? One share of CDXC stock can currently be purchased for approximately $4.56. How big of a company is Chromadex? Chromadex has a market capitalization of $253.17 million and generates $31.56 million in revenue each year. The company earns $-33,320,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. Chromadex employs 100 workers across the globe. What is Chromadex's official website? The official website for Chromadex is http://www.chromadex.com. How can I contact Chromadex? Chromadex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The company can be reached via phone at 310-388-6706 or via email at [email protected] MarketBeat Community Rating for Chromadex (NASDAQ CDXC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 357 (Vote Outperform)Underperform Votes: 373 (Vote Underperform)Total Votes: 730MarketBeat's community ratings are surveys of what our community members think about Chromadex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: What are defining characteristics of a correction? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.